Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224776 · ClinicalTrials.gov registry record · Phase 1
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
A Phase 1 study, sponsored by Brigham and Women's Hospital.
- Not yet
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT07224776 is a Phase 1 study that has not yet begun recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 20 participants.
The verdict
NCT07224776, a Phase 1 study, has not yet begun recruiting, sponsored by Brigham and Women's Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Single-center, open-label, two-stage pilot study examining the efficacy and safety of sparsentan for reducing high-grade proteinuria among patients with cancer who receive vascular endothelial growth factor inhibitors
Interventions
- DRUG sparsentan
- DRUG No sparsentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-06-10 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07224776
The ClinicalTrials.gov registry entry for NCT07224776 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sparsentan is the first listed.
NCT07224776 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07224776 about?
NCT07224776 is a clinical study titled "Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria". Single-center, open-label, two-stage pilot study examining the efficacy and safety of sparsentan for reducing high-grade proteinuria among patients with cancer who receive vascular endothelial growth factor inhibitors
What is the current status of trial NCT07224776?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-06-10. Estimated completion is 2028-12-01.
What interventions are being tested in trial NCT07224776?
The interventions under investigation include: sparsentan (DRUG), No sparsentan (DRUG).
Who is sponsoring clinical trial NCT07224776?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.